Objective: Data on the association between subclinical thyroid dysfunction and dementia are limited and conflicting. We aimed to determine whether subclinical thyroid dysfunction was associated with dementia and cognitive decline.
| INTRODUCTION
Subclinical thyroid dysfunction (SCTD), defined as abnormal TSH with normal free thyroxine (FT4), is strongly associated with age, with a prevalence of 4.5% for subclinical hyperthyroidism (SHyper) and 20% for subclinical hypothyroidism (SHypo) in the over-60 population. [1] [2] [3] Similarly, dementia is common with ageing, reaching a prevalence of 7%-10% after 60 years. 4 Cognitive impairment is associated with overt thyroid dysfunction, 5, 6 but data on SCTD are limited and conflicting. SHyper was associated with cognitive impairment or dementia in one retrospective 7 and two cross-sectional studies. 8, 9 Our recent meta-analysis of prospective cohorts found SHyper, but not SHypo, was associated with dementia, while decline in Mini-Mental State Examination (MMSE) was similar in both conditions, when compared with euthyroidism.
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However, most studies presented limitations: short time of follow-up, no dementia adjudication and incomplete assessment of potential confounding variables. 10 Additionally, study-level meta-analyses of observational studies are subject to potential bias (ecological fallacy) and do not allow reliable subgroup analyses, for example stratified by sex.
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If SCTD is associated with a higher risk of dementia, the mechanisms may be complex and at least partially depend on the relationship of SCTD with cardiovascular risk factors. 12 SCTD is indeed associated with coronary heart disease and arterial stiffness, with the latter a probable risk factor for vascular dementia. 12, 13 We examined in a large prospective cohort study of older adults with a long follow-up time and high-quality data, the association of SCTD with dementia and cognitive decline, and the potential role of cardiovascular risk factors in this relationship.
| MATERIALS AND METHODS

Reporting is in accordance with the STrengthening the Reporting of
OBservational studies in Epidemiology (STROBE) statement. 
| Cognitive assessment
Our primary outcome was incident-adjudicated dementia. Change in 3MS over time was our secondary outcome.
Dementia was adjudicated by an expert committee composed of a same panel of experienced medical doctors during the whole follow-up period. This committee identified dementia diagnosis on medical records using a predefined adjudication form. Dementia was defined by any of the following criteria: (i) ≥ 1. 
| Statistical analysis
For this analysis, baseline was defined as first TSH measurement, that is Year 2 visit, as previously done in Health ABC. 15 Participants who died before developing dementia were censored from the analysis at death date. 20, 21 Time-to-dementia was defined as the interval between baseline evaluation of thyroid function and first diagnosis of dementia or censoring from observation at the last available dementia evaluation. For all the analyses, we compared participants with SHyper with mildly decreased or suppressed TSH, and those with SHypo to euthyroids (reference).
We used a multivariable Cox regression model to assess the association between thyroid dysfunction and cause-specific incident dementia, taking into account baseline 3MS. [20] [21] [22] We presented results as hazards ratio (HR) with 95% confidence interval (CI). To generate cumulative incidence graphs, we used a competing-risks regression model, based on Fine and Gray's method, and took into account incidence of death. [20] [21] [22] To select the confounding factors, we first chose variables that may be confounding factors, based on previous publications and biological plausibility. The potential confounding factors included age, sex, race, education level, REALM, depression and study site. We then used a forward stepwise selection using the P-values of statistically significant associations with univariable analysis (P < .05). We adjusted for variables that were statistically significantly associated with both dementia and SCTD. Among them, age, sex, race and education level were significantly associated with both dementia and SCTD. We therefore adjusted the main analysis for those potential confounding factors. In a second model, we further adjusted for cardiovascular risk factors as they could additionally confound an association between SCTD and dementia. We tested the association of smoking status, alcohol consumption, physical activity, BMI, diabetes mellitus, blood pressure, lipid values, C-reactive protein, fasting glucose and glycated haemoglobin with both dementia and SCTD. We extended our final statistical models with those cardiovascular risk factors significantly associated with both dementia and SCTD: HDL-cholesterol, C-reactive protein, alcohol consumption and diastolic blood pressure.
In a secondary analysis, we analysed 3MS change from baseline to last follow-up. Because of 3MS non-normal distribution, we first cal- To improve statistical efficiency, we finally assessed the relationship of thyroid function with dementia and cognitive decline using fractional polynomials to capture the nonlinear association between TSH as a continuous variable and dementia or cognitive decline, adjusting for the same potential confounding factors as in the main anal-
ysis. Finally, we tested these associations using log-transformed TSH as a continuous variable. .001
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| RESULTS
| Baseline characteristics
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HDL, high-density lipoprotein; LDL, low-density lipoprotein; 3MS, Modified Mini-Mental State; N, number; REALM, Rapid Estimate of Adult Literacy in Medicine; SD, standard deviation; SHyper, subclinical hyperthyroidism; SHypo, subclinical hypothyroidism.
There were seven participants with missing data for education level, 139 for REALM, three for smoking status, eight for alcohol consumption, 19 for depression, 119 for total cholesterol, 113 for LDL-cholesterol and 82 for HDL-cholesterol. Values are mean (SD) or n (%). For some covariates, there were missing values that were excluded.
a P-value for the difference between euthyroidism and SHypo. Participants with SHyper with mildly decreased TSH were older and more likely to be women. Table 2 ).
| Subclinical thyroid dysfunction and risk of dementia
SHypo was not associated with dementia (adjusted HR = 0.91, 95%CI = 0.70;1.19, Table 2 ). We found no significant association of TSH with dementia in the continuous analysis using fractional polynomials (P = .10, Fig. S1 ) or using log-transformed TSH (P = .19, Fig. S2 ).
Results of the Cox regression were unchanged after further adjusting for cardiovascular risk factors (Table 2) . Results were similar in the sensitivity analysis excluding participants with thyroxine medication at baseline ( Table 2 ).
In the sensitivity analysis restricted to participants with thyroxine medication at baseline (N = 253), the adjusted HR for dementia 
| Subclinical thyroid dysfunction and change in 3MS
During the 10-year follow-up period, participants with SHyper with suppressed TSH had a larger decline in 3MS (adjusted 3MS mean change −3.89, 95%CI = −7.62;−0.15) than euthyroid participants (Table 3 and Figure 2 ). Conversely, we found no significant difference in adjusted 3MS mean change for participants with SHyper with mildly decreased TSH or SHypo (Table 3 and Figure 2 ). After further adjustment for cardiovascular risk factors, our results remained unchanged (Table 3 ). In the sensitivity analysis that excluded participants on thyroxine medication at baseline, point estimates were similar, but no longer statistically significant ( The main analysis was adjusted for age, sex, race, education level and 3MS at baseline. There were 7 missing values for education level, all in participants with euthyroidism (2 participants with dementia, 5 participants without dementia). Further adjustment for cardiovascular risk factors that were associated with subclinical thyroid dysfunction and dementia: high-density lipoprotein cholesterol (HDL-cholesterol), C-reactive protein, alcohol consumption and diastolic blood pressure. e Number of missing values for cardiovascular risk factors in the study population: n = 82 for HDL-cholesterol, n = 21 for C-reactive protein, n = 8 for alcohol consumption, n = 0 for diastolic blood pressure. f 253/2558 (9.9%) participants had thyroxine medication at baseline.
T A B L E 2 Adjusted hazard ratios for the risk of dementia in subclinical hyperthyroidism with suppressed TSH, subclinical hyperthyroidism with mildly decreased TSH and subclinical hypothyroidism, compared with euthyroidism 1 and 3, adjusted 3MS mean change was −3.07 (95%CI = −6.40;0. 25) for SHyper with suppressed TSH. Adjusted 3MS mean change was not associated with TSH as a continuous variable either in the fractional polynomials analysis (P = .17, Fig. S3 ) or as a log-transformed variable (P = .21, Fig. S4 ).
| DISCUSSION
In this prospective cohort of older community-dwelling adults, we found SHyper with suppressed TSH was associated with a higher risk of dementia and a larger decrease in cognition, while SHyper with mildly decreased TSH or SHypo was not. All results were similar after adjusting for cardiovascular risk factors.
Previous retrospective or cross-sectional studies showed an association of SHyper with dementia or cognitive impairment. [7] [8] [9] Although the association between SHyper and dementia was not significant in individual prospective studies, a recent meta-analysis of those studies found a HR for dementia of 1.67 (95% CI = 1.04;2.69) in SHyper. were not associated with faster decline in MMSE. 10 The differences in results might be explained by a relative short follow-up time in previous studies (33 months), and the modest sensitivity of MMSE compared to 3MS. 16 Furthermore, it may be due to the degree of SHyper, which was not assessed in previous studies, as in our study 3MS decline was not larger in participants with SHyper with mildly decreased TSH. We found no previous study using 3MS.
Several pathophysiological pathways could explain the relationship between hyperthyroid dysfunction and dementia. First, dementia may be caused by an increase in neuronal necrosis 24 and oxidative stress associated with both hyperthyroidism 25 and Alzheimer's disease.
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Second, a genetic susceptibility may exist, as some thyroid hormones target genes are involved in neurogenesis. 27 Third, dementia could be caused by lower choline in the brain, as described in Alzheimer's disease. 28 In a pilot study, choline/creatine ratio in the brain was indeed lower in patients with untreated Graves' disease, but normalized after treatment. 29 We hypothesize that the relationship between SHyper and cognitive function may run along similar paths. with subclinical thyroid dysfunction and dementia: high-density lipoprotein cholesterol (HDL-cholesterol), C-reactive protein, alcohol consumption and diastolic blood pressure. e Number of missing values for cardiovascular risk factors in the study population: n = 82 for HDL-cholesterol, n = 21 for C-reactive protein, n = 8 for alcohol consumption, n = 0 for diastolic blood pressure. f 253 of 2558 (9.9%) participants had thyroxine medication at baseline.
We found no significant association of SHypo with either dementia or cognitive decline. This is consistent with the results of two previous meta-analyses 10, 32 and of the recent TRUST trial that found no benefit of thyroxine replacement on executive cognitive function as measured by the letter-digit coding test. 33 Conversely, another meta-analysis found a significant association in participants younger than 75 years only. 34 These conflicting findings may be related to the older age of our participants. However, the results of this latter meta-analysis should be interpreted in the light of some limitations, as it included heterogeneous study designs (both retrospective and prospective studies) and did not assess dementia as an end-point, and as the TRUST trial did not find different results according to age. Second, the prospective design of the study allows a risk assessment and avoids potential bias related to retrospective analyses.
Third, the follow-up time was longer than in most previous studies (median 9 years versus 44.4 months in the recent meta-analysis of prospective cohort studies). 10 Fourth, we assessed a large number of potential confounding factors, including cardiovascular risk factors, and performed stratified analyses to identify potentially relevant interactions. Fifth, we studied both dementia and cognitive decline; while some subjectivity may remain when diagnosing dementia, the 3MS is an objective, sensitive and validated test to identify cognitive impairment. Sixth, we assessed thyroid function not only using TSH as a continuous variable, but also according to categories of SCTD, which may be clinically more relevant. Finally, unlike in most previous studies, diagnosis of dementia was adjudicated by an expert committee, reducing the risk of misclassification, and was based on several criteria including not only clinical diagnosis, but also the objective 3MS, as well as the prescription of dementia drugs.
In conclusion, in this prospective cohort study, we found that 
